ID | 52782 |
フルテキストURL | |
著者 |
Hayashi, Tatsuro
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Asano, Hiroaki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Kaken ID
Toyooka, Shinichi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Tsukuda, Kazunori
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
ORCID
Kaken ID
publons
researchmap
Soh, Junichi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
ORCID
Kaken ID
researchmap
Shien, Tadahiko
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
ORCID
Kaken ID
publons
researchmap
Taira, Naruto
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Kaken ID
publons
Maki, Yuho
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Tanaka, Norimitsu
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Doihara, Hiroyoshi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Kaken ID
researchmap
Nasu, Yasutomo
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Urol
Kaken ID
publons
researchmap
Huh, Nam-ho
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cell Biol
Miyoshi, Shinichiro
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Kaken ID
publons
researchmap
|
抄録 | The REIC (reduced expression in immortalized cells)/Dkk-3 is down-regulated in various cancers and considered to be a tumor suppressor gene. REIC/Dkk-3 mRNA has two isoforms (type-a,b). REIC type-a mRNA has shown to be a major transcript in various cancer cells, and its promoter activity was much stronger than that of type-b. In this study, we examined the methylation status of REIC/Dkk-3 type-a in a broad range of human malignancies.
We examined REIC/Dkk-3 type-a methylation in breast cancers, non-small-cell lung cancers, gastric cancers, colorectal cancers, and malignant pleural mesotheliomas using a quantitative combined bisulfite restriction analysis assay and bisulfate sequencing. REIC/Dkk-3 type-a and type-b expression was examined using reverse transcriptional PCR. The relationships between the methylation and clinicopathological factors were analyzed.
The rate of REIC/Dkk-3 type-a methylation ranged from 26.2 to 50.0% in the various primary tumors that were examined. REIC/Dkk-3 type-a methylation in breast cancer cells was significantly heavier than that in the other cell lines that we tested. REIC/Dkk-3 type-a methylation was inversely correlated with REIC/Dkk-3 type-a expression. There was a correlation between REIC/Dkk-3 type-a and type-b mRNA expression. REIC/Dkk-3 type-a expression was restored in MDA-MB-231 cells using 5-aza-2'-deoxycytidine treatment. We found that estrogen receptor-positive breast cancers were significantly more common among the methylated group than among the non-methylated group.
REIC/Dkk-3 type-a methylation was frequently detected in a broad range of cancers and appeared to play a key role in silencing REIC/Dkk-3 type-a expression in these malignancies.
|
キーワード | DNA methylation
REIC/Dkk-3
Breast cancer
Lung cancer
Mesothelioma
|
発行日 | 2012-05
|
出版物タイトル |
Journal of Cancer Research and Clinical Oncology
|
巻 | 138巻
|
号 | 5号
|
出版者 | Springer
|
開始ページ | 799
|
終了ページ | 809
|
ISSN | 0171-5216
|
資料タイプ |
学術雑誌論文
|
関連URL | http://ousar.lib.okayama-u.ac.jp/metadata/52511
|
言語 |
英語
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
Web of Science KeyUT |